2024 Trends in Drug Benefit Design Report Webinar

PSG announces the results of its extensive research on the latest trends in drug benefit design.

Plan sponsors face complex decisions and challenges as they build and implement their drug benefit. PSG’s 2024 Trends in Drug Benefit Design Report provides a view into how plans work to achieve access and affordability for members while controlling their pharmacy spend.

Sponsored by Prescryptive Health, the report contains valuable insights from benefits leaders representing plans nationwide.

Watch the Recording

Key Findings

One in four health plans are moderately or very likely to pursue an unbundled PBM services arrangement
Over 90% of plans cover GLP-1 drugs for type 2 diabetes, while just over 30% cover these drugs for obesity
- About three-quarters of plans have experienced increased GLP-1 drug spend in recent months
- The most common strategies used to control costs related to coverage of GLP-1 drugs for obesity are prior authorization and a BMI requirement
Employers are moderately concerned about the impact of high list price/high rebate drugs on their high-deductible health plan members
1 in 5 plans have a process for tracking health disparities among plan members, and many are unsure what actionable role their organization should play in supporting health equity